Authors' objectives: Breast cancer is the most common cancer in the UK. Most women who get breast cancer are over 50 years of age and have already gone through the menopause. However, younger women, and in rare cases, men, may also get breast cancer. There are many types of breast cancer. Triptorelin is a new treatment for a type of early breast cancer that usually occurs in younger women who have not gone through the menopause, and is described as hormone receptor-positive. Triptorelin is given as an injection straight into a muscle every 28 days along with hormonal therapy tablets that are already widely used for breast cancer. Studies at the moment are aiming to show how well these treatments work together and that triptorelin is safe to use. If triptorelin is licenced for use in the UK, it will provide a new treatment option for this patient group.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/triptorelin-decapeptyl-sr-for-premenopausal-women-with-early-endocrine-responsive-breast-cancer/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)